Omalizumab for severe allergic asthma: dollars and sense.
Krishnan
Jerry A
JA
Gould
Michael
M
D018927:Anti-Asthmatic Agents / Q000191:economics* / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D000069444:Omalizumab; D012130:Respiratory Hypersensitivity / Q000188:drug therapy*
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab